Papers/PMID:37767399
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.
Frontiers in pharmacology2023The record
5 findings · 1 compound · 5 endpoints · 4 null
What it reported
How to read these marksWhat moved
1 finding
resveratrol — decreases LDL cholesterol
SpeculativeGrade F, Speculative. Mechanistic inference, no evidence found, or evidence weakened below D.Findingreplicated ×2“Compared with model group, the resveratrol group manifested a significant reducing effect on LDL-C level [SMD = −2.01, 95% CI (−2.77, −1.25), p < 0.0001] (Supplementary Figure S3A A).”
Quoted verbatim from Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.. - Study
- animal · not in humans
- Participants
- 208
- Dose
- 20-400 mg/kg, 4-20 weeks, pooled across studies
- Population
- rodents with diet-induced NAFLD models, resveratrol vs model/control group, preclinical meta-analysis, 13 studies, 208 animals
Effect -2.01 standardised mean difference, 95% CI -2.77 to -1.25
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.2023PMID:37767399Permalink
What did not
4 findings
resveratrol — no detected effect on aspartate aminotransferase
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.FindingNull result“Interestingly, the result suggested that there was no significant efficacy of resveratrol on ALT level in NAFLD patients [SMD = −0.16, 95% CI (−0.67, 0.35), p = 0.542], nor was the efficacy in AST [SMD = −0.39, 95% CI (−0.95, 0.16), p = 0.167].”
Quoted verbatim from Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.. - Study
- meta-analysis
- Dose
- 300-3,000 mg/day, 8-24 weeks, pooled across trials
- Population
- adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
Effect -0.39 standardised mean difference, 95% CI -0.95 to 0.16
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.2023PMID:37767399Permalink
resveratrol — no detected effect on body mass index
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.FindingNull result“The result indicated that there was just the trend of decrease but no significance after treatment with resveratrol compared with placebo in BW [SMD = − 0.08, 95% CI (−0.35, 0.18), p = 0.544], BMI [SMD = − 0.07, 95% CI (−0.33, 0.20), p = 0.633], WC [SMD = −0.73, 95% CI (−1.97, 0.51), p = 0.249] and WHR [SMD = −0.12, 95% CI (−0.40, 0.16), p = 0.405] (Supplementary Figures S14, 15).”
Quoted verbatim from Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.. - Study
- meta-analysis
- Dose
- 300-3,000 mg/day, 8-24 weeks, pooled across trials
- Population
- adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
Effect -0.07 standardised mean difference, 95% CI -0.33 to 0.2
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.2023PMID:37767399Permalink
resveratrol — no detected effect on waist-to-hip ratio
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.FindingNull result“The result indicated that there was just the trend of decrease but no significance after treatment with resveratrol compared with placebo in BW [SMD = − 0.08, 95% CI (−0.35, 0.18), p = 0.544], BMI [SMD = − 0.07, 95% CI (−0.33, 0.20), p = 0.633], WC [SMD = −0.73, 95% CI (−1.97, 0.51), p = 0.249] and WHR [SMD = −0.12, 95% CI (−0.40, 0.16), p = 0.405] (Supplementary Figures S14, 15).”
Quoted verbatim from Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.. - Study
- meta-analysis
- Dose
- 300-3,000 mg/day, 8-24 weeks, pooled across trials
- Population
- adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
Effect -0.12 standardised mean difference, 95% CI -0.4 to 0.16
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.2023PMID:37767399Permalink
resveratrol — no detected effect on alanine aminotransferase
SuggestiveGrade C, Suggestive. Human evidence with several recorded weaknesses, or a design that tops out at C.FindingNull result“Interestingly, the result suggested that there was no significant efficacy of resveratrol on ALT level in NAFLD patients [SMD = −0.16, 95% CI (−0.67, 0.35), p = 0.542], nor was the efficacy in AST [SMD = −0.39, 95% CI (−0.95, 0.16), p = 0.167].”
Quoted verbatim from Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.. - Study
- meta-analysis
- Dose
- 300-3,000 mg/day, 8-24 weeks, pooled across trials
- Population
- adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
Effect -0.16 standardised mean difference, 95% CI -0.67 to 0.35
Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.2023PMID:37767399Permalink